Takeda Ups Full-Year Guidance on Slower Vyvanse Generic Erosion

To read the full story

• Sign In
• Subscribe

Related Article

• Vyvanse Generics Drag Takeda Earnings; FY2025 Outlook Trimmed
  October 31, 2025

• Takeda Sees Limited Tariff Exposure as US Remains Strategic Priority
  July 31, 2025

• Takeda on Course to Stable Growth as Late-Stage Assets Near Market
  May 9, 2025

• Takeda’s Japan Sales Ratio Falls Below 10%, Global Biz Thrives in H1
  November 1, 2024

• Takeda’s Operating Profit Dips by More than Half in FY2023
  May 10, 2024

• Takeda’s April-December Sales Up 4.6%, but Flat at CER
  February 2, 2024

• Takeda’s H1 Profit Tumbles on Write-Down Tied to Trial Setbacks, Outlook Slashed
  October 27, 2023

• Takeda Q1 Sales Up 8.9%, Led by Key Product Growth and Weak Yen
  July 28, 2023

• Takeda Logs Record Sales, Breaks 4 Trillion Yen Mark in FY2022
  May 12, 2023

• Takeda Logs Double-Digit Growth, Led by Core Products and Weaker Yen
  February 3, 2023

• Takeda’s H1 Sales Up 10% Backed by Robust Mainstays, Hefty FX Gains
  October 28, 2022

• Takeda’s Q1 Sales Up 2.4% Despite Diabetes Divesture Last Year, Gets Hefty FX Gains
  July 29, 2022

• Takeda Poised to Weather LOEs in Next 2 Years with 10 Growth Drivers: CEO
  May 12, 2022

• Takeda’s FY2021 Sales Up 11.6%; Weak Yen Tailwind for Revenue, but Drags Profits
  May 12, 2022

• Takeda Delivers Growth in All Focus Therapeutic Areas in April-December
  February 4, 2022

• Takeda’s H1 Sales Log Two-Digit Growth Driven by Global Brands, FDA Wraps Up Plant Re-Inspection
  October 29, 2021

• Takeda’s Q1 Sales Rise on Diabetes Divestiture; Plant Re-Inspection Results Expected Late October
  August 2, 2021